Allogene Therapeutics, Inc. Impairment of Leasehold
Allogene Therapeutics, Inc. (ALLO) reported Impairment of Leasehold of $100.00 thousand for the 3-month period ending 2025-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLeasehold · last filed 2026-08-12
- Allogene Therapeutics, Inc. impairment of leasehold for the quarter ending 2025-06-30 was $100.00K.
| Period end | Impairment of Leasehold 3 month |
|---|---|
| 2025-06-30 | $100.00K 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |